Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

BACKGROUND: Ipilimumab improves survival in patients with advanced melanoma. The activity and safety of ipilimumab outside of a clinical trial was assessed in an expanded access programme (EAP). METHODS: Ipilimumab was available upon physician request for patients aged 16 or over with pretreated sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo A, Simeone, Ester, Sileni, Vanna Chiarion, Pigozzo, Jacopo, Maio, Michele, Altomonte, Maresa, Del Vecchio, Michele, Di Guardo, Lorenza, Marchetti, Paolo, Ridolfi, Ruggero, Cognetti, Francesco, Testori, Alessandro, Bernengo, Maria Grazia, Guida, Michele, Marconcini, Riccardo, Mandalà, Mario, Cimminiello, Carolina, Rinaldi, Gaetana, Aglietta, Massimo, Queirolo, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030525/
https://www.ncbi.nlm.nih.gov/pubmed/24885479
http://dx.doi.org/10.1186/1479-5876-12-116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030525/
https://www.ncbi.nlm.nih.gov/pubmed/24885479
http://dx.doi.org/10.1186/1479-5876-12-116

Ejemplares similares